Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Olmutinib (BI1482694) 是一种新型表皮生长因子受体酪氨酸激酶抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 248 | 现货 | ||
2 mg | ¥ 355 | 现货 | ||
5 mg | ¥ 578 | 现货 | ||
10 mg | ¥ 980 | 现货 | ||
25 mg | ¥ 1,830 | 现货 | ||
50 mg | ¥ 3,160 | 现货 | ||
100 mg | ¥ 4,320 | 现货 | ||
200 mg | ¥ 6,250 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 638 | 现货 |
产品描述 | Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor |
体外活性 | Olmutinib at 3 μM significantly reversed drug resistance mediated by ABCG2, but not by ABCB1 and ABCC1, by antagonizing the drug efflux function in ABCG2-overexpressing cells.?In addition, olmutinib at reversal concentration affected neither the protein expression level nor the localization of ABCG2.?The results observed from the accumulation/efflux study of olmutinib showed that olmutinib reversed ABCG2-mediated MDR with an increasing intracellular drug accumulation due to inhibited drug efflux.?We also had consistent results with the ATPase assay that olmutinib stimulated ATPase activity of ABCG2 up to 3.5-fold.?Additionally, the molecular interaction between olmutinib and ABCG2 was identified by docking simulation.?Olmutinib not only interacts directly with ABCG2 but also works as a competitive inhibitor of the transport protein[1] |
别名 | HM61713, BI1482694 |
分子量 | 486.59 |
分子式 | C26H26N6O2S |
CAS No. | 1802181-20-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (113.03 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0551 mL | 10.2756 mL | 20.5512 mL | 51.378 mL |
5 mM | 0.411 mL | 2.0551 mL | 4.1102 mL | 10.2756 mL | |
10 mM | 0.2055 mL | 1.0276 mL | 2.0551 mL | 5.1378 mL | |
20 mM | 0.1028 mL | 0.5138 mL | 1.0276 mL | 2.5689 mL | |
50 mM | 0.0411 mL | 0.2055 mL | 0.411 mL | 1.0276 mL | |
100 mM | 0.0206 mL | 0.1028 mL | 0.2055 mL | 0.5138 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Olmutinib 1802181-20-9 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR HM 61713 HM61713 HM-61713 BI1482694 BI-1482694 BI 1482694 1353550-13-6 Inhibitor inhibitor inhibit